- ImmuCell press release ( NASDAQ: ICCC ): FY GAAP EPS of -$0.32.
- Revenue of $18.57M (-3.5% Y/Y).
- EBITDA (a non-GAAP financial measure described on page 5 of this press release) decreased to approximately $350,000 during the year ended December 31, 2022 from $2,706,000 during the year ended December 31, 2021.
- Cash and cash equivalents decreased to $5.8 million as of December 31, 2022 from $10.2 million as of December 31, 2021.
- Net working capital decreased to approximately $10.9 million as of December 31, 2022 from $13.7 million as of December 31, 2021.
- Stockholders’ equity decreased to $30.4 million as of December 31, 2022 from $32.6 million as of December 31, 2021.
For further details see:
ImmuCell GAAP EPS of -$0.32, revenue of $18.57M